Dr. Forrest C. Jellison, MD

Dr. Jellison practices at Loma Linda University Medical Cente - Center for Restorative Neurology - HOPD in Loma Linda, California.

Dr. Jellison's NPI, 1508073511, was assigned on May 17, 2007. Dr. Jellison graduated from Loma Linda University School Of Medicine in 2005. Dr. Jellison holds California license A98781.

Dr. Jellison's primary practice is Loma Linda University Medical Cente - Center for Restorative Neurology - HOPD, at 11370 Anderson St, Loma Linda, CA 92354.

Dr. Jellison's primary practice is Loma Linda University Medical Cente - Center for Restorative Neurology - HOPD in Loma Linda, California. Dr. Jellison is also affiliated with Loma Linda University Medical Center. The medical group on file is Loma Linda University Faculty Medical Group (LLUFMG). Dmand AI also links Dr. Jellison to 3 more hospitals, 4 group practices and clinics, 3 medical groups and 1 hospital outpatient department, each named with a free account. Dr. Jellison's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Jellison practices, 10 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Jellison's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Jellison is board certified in female pelvic medicine and reconstructive surgery by the American Board of Urology. Dmand AI has Dr. Jellison's licenses on file in 2 states: California and Texas.

Dmand AI lists bladder disease, enlarged prostate, erectile dysfunction, kidney removal surgery, kidney stone disease, pelvic prolapse, prostate cancer and urinary endoscopy among the conditions Dr. Jellison treats.

CMS data shows 654 Medicare services from Dr. Jellison across 16 procedure codes in 2024, for 275 Medicare patients. Medicare paid $51,351 for them.

CMS counts 275 Medicare patients who saw Dr. Jellison in 2024. The largest group is 65 to 74, with 100 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 40% are also on Medicaid. Their average risk score is 2.08, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Jellison's median patient age at 68, with 43% women.

In 2024, Dr. Jellison wrote 1,039 Medicare Part D claims for 286 patients. 86% of them were for generic drugs. CMS names the drug for 945 of them, across 15 drugs with 11 or more claims each, at $123,596 in total drug cost. In 2023, CMS named 690 claims across 12 drugs.

Dr. Jellison accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Jellison as offering telehealth.

Prostate resection: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 12 papers to Dr. Jellison, published from 2019 to 2025. 2019 was the busiest year, with 2. The most frequent topics are Body Mass Index, Equipment Design and Mindfulness. Dr. Jellison has published most often in J Endourol. Dr. Jellison's most frequent co-authors are Pansy Uberoi, MD, MPH, Kamyar Yehudah Ebrahimi, MD and Andrea Staack, MD.

Dmand AI links Dr. Jellison to 3 clinical trials. 1 is still active or recruiting. Conditions studied include Urinary Bladder, Overactive, Prostatic Neoplasms and Urinary Incontinence, Stress.

CMS Open Payments shows 77 general payments to Dr. Jellison from 15 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 73% of the total. Medtronic USA, Inc. paid the most, $2,451.

Dr. Jellison graduated from Loma Linda University School Of Medicine in 2005.

Dr. Jellison is in network with 15 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.